Clinical Trial Update: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study [Phase 2]

View source ↗

Summary

A Phase II investigator-initiated trial evaluating safety and tolerability of everolimus as second-line therapy in poorly differentiated neuroendocrine carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor
• Poorly Differentiated Malignant Neuroendocrine Carcinoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3 | Phase 2 | Status: COMPLETED